Actos Bladder Cancer Allegations Attorney Help: Resource4thePeople Informing Consumers about $9 Billion-Dollar Jury Verdict Awarded to Victim

Share Article

Huge amount of damages awarded to New York man who was diagnosed with bladder cancer that jurors were told was caused by diabetes drug Actos. National network of attorneys continues offer of no-cost consultations to consumers seeking compensation over similar claims.

Resource4thePeople today announced that it is providing consumers who may have been affected by Actos bladder cancer allegations that a Louisiana jury* has awarded a man over $9 billion in damages over his claims that his use of the diabetes medication caused him to develop the disease.

The case was the first to go to trial from a Multidistrict Litigation in U.S. District Court in Louisiana in which thousands** of Actos lawsuits filed over allegations of bladder cancer have been consolidated under a single federal judge.

Jurors awarded the compensation to Terrence Allen, who said that he was treated for his diabetes for five years before he was diagnosed with bladder cancer in 2011. Allen had sued Takeda Pharmaceuticals and its U.S. partner Eli Lilly in the case.*

"This huge award came in the first trial in which plaintiffs for victims who are alleging that their use of Actos to treat diabetes caused them to develop bladder cancer and that the defendants did not properly warn them of this danger," said Resource4thePeople.

"We have now posted details of this award on our web site and are also continuing to offer free consultations to consumers who may have been affected by similar allegations and wish to explore their legal options to seek compensation as result of developing bladder cancer."

Meanwhile, testimony continues in another trial*** in Nevada in which two plaintiffs are seeking another multibillion dollar award for their allegations of developing bladder cancer from the use of Actos.

The trial has been underway for several weeks with lawyers for two Clark County women in their 80s seeking compensatory and punitive damages against Takeda Pharmaceuticals, manufacturer of Actos (pioglitazone), according to the court file in the case.

"Due to Takeda Pharmaceutical’s conscious decision to keep this information from consumers and their doctors, we now have patients who are left to bear the permanent injury caused by Actos,” one of the plaintiffs' lawyers told the Las Vegas Review-Journal in a March 9, 2014 report.**** “That’s why we will be asking for over a billion-dollar punitive damage verdict.”

"The news of developments in these Actos lawsuits alleging that the medication may cause bladder cancer has caused a huge increase in the number of inquiries we are receiving from consumers seeking information about their options to seek compensation over these allegations," said Resource4thePeople.

"Therefore we will continue to provide these consultations to consumers who are inquiring about whether they are eligible to file a lawsuit in connection with these allegations and are seeking experienced, aggressive legal representation."

Resource4thePeople is also informing consumers that it will keep them abreast of the latest development in litigation involving allegations in lawsuits that Actos may cause bladder cancer.

Resource4thePeople has found a significant increase in consumer interest about their legal options over bladder cancer allegations after the release of a June 15, 2011 Food and Drug Administration safety announcement.*****

The FDA safety announcement was issued after the agency reviewed a study sponsored by Takeda Pharmaceuticals which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.

Here is part of the safety announcement:

“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines."

Two other trials outside this litigation were held in 2013 in which juries returned verdicts against Takeda Pharmaceuticals involving allegations that the medication can lead to bladder cancer.

In one case a Maryland jury awarded****** of $1.7 million to the family of a man who alleged that his use of Actos caused him to die of bladder cancer. That verdict was overturned after the judge found that the victim’s 30-year smoking habit contributed to his death.

The Maryland case was the second in which a jury found in favor of a plaintiff alleging that Takeda Pharmaceuticals was liable over bladder cancer but had the damages overturned on legal technicalities, according to court documents.

The Maryland case was preceded by one in California where a jury found in April that Takeda should pay $6.5 million in damages over similar allegations, according to the court file in that case.*******

Bloomberg News reported Sept. 26, 2013 that Takeda Pharmaceuticals, which is Asia's largest drug manufacturer, has been named in "more than 3,000 suits over the drug."********

The report cited important facts about the Maryland case:

"A Maryland jury ruled that Takeda Pharmaceutical Co. (4502) didn’t properly warn an ex-U.S. Army translator and his doctor about the risks of its Actos diabetes drug and ordered the company to pay more than $1.7 million in damages."


  • Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, Case # 6:12-cv-00064, U.S. District Court for the Western District of Louisiana

**In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
***Case # A-13-680556-C, Triana vs. Takeda Pharmaceuticals, Nevada District Court, Clark County
******An v. Nieberlein, Case # 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland
*******Cooper v. Takeda Pharmaceuticals America Inc., Case #CGC-12-518535, California Superior Court, Los Angeles

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bill Callahan
+1 858 602-2749
Email >
Visit website